News | April 07, 2022
BIO KOREA, Asia's Biggest Bio-Health Convention, to open in May 2022
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Dupixent peak sales ambition raised to more than €13 billion
Subscribe To Our Newsletter & Stay Updated
